Capture insight · MA Intelligence Hub

Source

Engagement: ENG-0064 · Scientific exchange · 2026-07-28
Stakeholder: Dr. Farah Kimura · Thoracic medical oncologist, Memorial Sloan Kettering (US)
Topics discussed: Chemotherapy-free first line

Product

Safety flag (potential adverse event)

Original text

Verbatim observation. Stored unchanged; the summary below is what gets edited.

Suggestions are drafts; you approve the final values.

Structured summary

Fill in manually or generate a suggestion

Summary

Prioritisation score

Rate each dimension 1–5. Weights are fixed by the governance board.

Medium 58

Patient relevanceweight 20%3Strategic alignmentweight 20%3Scientific importanceweight 15%3Urgencyweight 15%3Noveltyweight 10%3Actionabilityweight 10%3Confidenceweight 5%3Breadth of occurrenceweight 5%1